Livzon Pharmaceutical (000513) Q3 2025 earnings summary

Executive summary

• Revenue for Q3 2025 reached ¥2.84 billion, up 1.60% year-over-year; nine-month revenue totaled ¥9.12 billion, up 0.38% year-over-year.

• Net profit attributable to shareholders for Q3 was ¥473 million, down 5.73% year-over-year; nine-month net profit was ¥1.75 billion, up 4.86% year-over-year.

• Operating cash flow for the first nine months was ¥2.53 billion, up 9.42% year-over-year.

Financial highlights

• Basic and diluted EPS for Q3 were ¥0.52, down 3.70% year-over-year; nine-month EPS was ¥1.96, up 8.29% year-over-year.

• Gross margin and operating profit details not explicitly stated, but net profit margin improved over nine months.

• Total assets at period end were ¥24.54 billion; equity attributable to shareholders was ¥13.96 billion.

Outlook and guidance

• No explicit forward-looking guidance provided, but increased R&D investment and cash management activities suggest ongoing business development.